JY-1-106: a BH3 alpha-helix mimetic that functions as a pan-Bcl-2 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 57338853 |
| CHEMBL ID | 4077940 |
| SCHEMBL ID | 23758400 |
| MeSH ID | M0592703 |
| Synonym |
|---|
| CHEMBL4077940 , |
| bdbm50266958 |
| 4-(5-(4-amino-3-isopropoxybenzamido)-6-isopropoxypicolinamido)-3-isopropoxybenzoic acid |
| jy-1-106 |
| GLXC-15062 |
| SCHEMBL23758400 |
| 1373319-35-7 |
| AKOS040752219 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | Ki | 0.1790 | 0.0000 | 0.1901 | 2.9000 | AID1599472 |
| Bcl-2-like protein 1 | Homo sapiens (human) | IC50 (µMol) | 0.3940 | 0.0003 | 1.0482 | 9.5400 | AID1483492 |
| Induced myeloid leukemia cell differentiation protein Mcl-1 | Homo sapiens (human) | IC50 (µMol) | 10.1050 | 0.0044 | 2.9235 | 10.0000 | AID1483493; AID1858770 |
| Induced myeloid leukemia cell differentiation protein Mcl-1 | Homo sapiens (human) | Ki | 1.7900 | 0.0010 | 1.4653 | 9.5400 | AID1599473; AID1858825 |
| Bcl-2 homologous antagonist/killer | Homo sapiens (human) | IC50 (µMol) | 10.2100 | 0.0100 | 0.0335 | 0.0570 | AID1858770 |
| Bcl-2 homologous antagonist/killer | Homo sapiens (human) | Ki | 1.7900 | 0.0010 | 2.7182 | 9.0000 | AID1858825 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1483492 | Inhibition of FITC-labeled Bak-BH3 peptide binding to Bcl-xL (unknown origin) by fluorescence polarization assay | 2017 | Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3 | Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules. |
| AID1858770 | Inhibition of Bak/Mcl-1 (unknown origin) protein protein interaction by fluorescence polarization assay | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | Development of Mcl-1 inhibitors for cancer therapy. |
| AID1599472 | Inhibition of FITC-Ahx-GQVGRQLAIIGDDINR-CONH2 peptide binding to Bcl2 (unknown origin) by fluorescence polarization assay | 2019 | European journal of medicinal chemistry, Sep-01, Volume: 177 | The chemical biology of apoptosis: Revisited after 17 years. |
| AID1858825 | Binding affinity to Bak/Mcl-1 (unknown origin) protein protein interaction by fluorescence polarization assay | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | Development of Mcl-1 inhibitors for cancer therapy. |
| AID1599473 | Inhibition of FITC-Ahx-GQVGRQLAIIGDDINR-CONH2 peptide binding to MCl-1 (unknown origin) by fluorescence polarization assay | 2019 | European journal of medicinal chemistry, Sep-01, Volume: 177 | The chemical biology of apoptosis: Revisited after 17 years. |
| AID1858769 | Inhibition of Bak/Bcl-xL (unknown origin) protein protein interaction by fluorescence polarization assay | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | Development of Mcl-1 inhibitors for cancer therapy. |
| AID1858826 | Binding affinity to Bak/Bcl-xL (unknown origin) protein protein interaction by fluorescence polarization assay | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | Development of Mcl-1 inhibitors for cancer therapy. |
| AID1483493 | Inhibition of FITC-labeled Bak-BH3 peptide binding to Mcl-1 (unknown origin) by fluorescence polarization assay | 2017 | Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3 | Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (50.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (50.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||